Sitemap > News
Displaying 1 - 50 of 9782 results
- Positive Final Data from HyCAMPTM Phase II Trial in Metastatic Colorectal Cancer
- FDA approves XYZAL® tablets for the treatment of seasonal and year round allergies, and chronic urticaria
- Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
- Rexahn Pharmaceuticals Receives FDA Approval to Initiate a Phase II trial for Archexin in Patients with Renal Cell Carcinoma
- ENTREMED COMMENCES PHASE 2 CLINICAL TRIAL COMBINING PANZEM® NCD AND TEMODAR® IN BRAIN CANCER PATIENTS
- Positive Phase I Clinical Results for LCP-Tacro
- Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B® in Systemic Lupus Erythematosus
- FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
- Progenics and Wyeth Announce FDA Has Accepted for Filing the New Drug Application for Subcutaneous Methylnaltrexone
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Serenex Announces Initiation of Phase 1 Trial for Oral HSP90 Inhibitor, SNX-5422
- Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
- Cobalis Announces Delay in Reporting of Phase III Trial Results for PreHistin™ in Seasonal Allergic Rhinitis
- Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
- Celsion Completes Enrollment In Phase I Liver Cancer Study
- Data Show Improved Response Rate when Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
- Epeius Biotechnologies Gains Fda Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
- Telik Reports Results of TELCYTA® ASSIST-3 Trail
- Telik Announces Top-Line Results of TELCYTA® ASSIST-2 Trial
- Telik Reports Results of TELCYTA® ASSIST-1 Trail
- Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
- Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
- Æterna Zentaris Presents Detailed Phase 1 Results for Anti-Cancer Compound AEZS-108 at ASCO Meeting
- ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
- ARIAD Presents Positive Efficacy Data On AP23573, Novel mTOR Inhibitor, in Phase 2 Metastatic Endometrial Cancer Trial
- Biweekly Xeloda® Dosing Regimen Is Well Tolerated in Advanced Breast Cancer
- Xeloda® Plus Avastin® Combination Delays Disease Progression in Women with Advanced Breast Cancer
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
- Cardiome and Astellas Announce Positive Results from ACT 2 Trial
- Clinical Data Suggest Potential Versatility of ALIMTA® (Pemetrexed for Injection)-Based Regimens in Lung Cancer
- Study Supports Activity of GEMZAR® (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
- Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
- CytImmune Presents Positive CYT-6091 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- EntreMed Presents Phase 2 Results for Panzem® Capsules in Multiple Myeloma
- Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
- Exelixis Reports Comprehensive XL880 Phase I Data At ASCO
- GlaxoSmithKline reports positive new data On Tykerb® (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting
- 8-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR®
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
- Introgen Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
- Investigational Drug CEDIRANIB (AZD2171) Shows Promise In Patients With Recurrent Glioblastoma (GBM)
- Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
- Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
- Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
- Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
- New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
- Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 Next >